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Capsaicin 8% patch is cost-effective compared to pregabalin for patients who have 
failed one or more previous systemic treatments for PNP.
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Objectives: Multiple regimens are used in the treatment of severe haemophilia A 
in the Netherlands. Most patients receive clotting factors intravenously 2-3 times 
weekly to prevent bleedings: intermediate dose prophylaxis. Given the high utili-
zation of prophylaxis treatment, budget restraints might hinder the availability of 
prophylaxis for patients in the nearby future. Other treatment regimens are on-
demand (OD) treatment, administering clotting factors in case of bleedings, and 
prophylaxis treatment with a switch to OD at 18 years. This analysis estimates 
the cost-effectiveness of Dutch prophylaxis treatment for severe haemophilia A 
patients compared to other treatment regimens. MethOds: A Markov model is 
developed with the health stages ‘Alive’, ‘Severe joint damage’ and ‘Death’. Bleeding 
rates of individual patients are simulated over lifetime, including a probability of 
inhibitor development. A higher joint bleed rate is accompanied by increased joint 
damage, increasing the chance of joint surgery. Disease progression, within the 
Alive health state, is modeled with the Pettersson Score (PS). The PS indicates the 
radiographic arthropathy. Increased joint damage is associated with physical limita-
tions and decreased QoL. Because the chosen treatment regimen affects both the 
joint bleed rate and inhibitor development, it also affects the HRQoL. The analysis 
was performed from a societal perspective. Results: Prophylaxis treatment was 
associated with the greatest QoL. The cost-effectiveness acceptability curve shows 
a probability of 90% for prophylaxis treatment to be cost-effective at a threshold of 
€ 0, - compared to OD treatment. Compared to prophylaxis with a switch to OD at 
18 years, prophylaxis treatment has a 50% probability of being cost-effective at a 
€ 80.000, - threshold. The model outcome is sensitive for variations in bleeding rate, 
prophylaxis dosage, inhibitor development and utilities. cOnclusiOns: Based on 
our model, treatment of severe haemophilia A patients with lifetime prophylaxis 
is cost-effective compared to OD treatment.
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Objectives: The objective of the analysis was to evaluate costs and outcomes 
of treating post-herpetic neuralgia (PHN), a chronic disease with severe burden 
for patients, in the Netherlands with lidocaine 5% medicated plaster compared to 
pregabalin and amitriptyline. MethOds: A Markov model was used to extrapolate 
outcomes beyond the time horizon of the available trial data and to allow for the 
fact that patients may discontinue treatment at any point during treatment. Costs 
and effects, expressed in terms of the quality-adjusted life-year (QALY) gained, 
were calculated for each treatment strategy over a period of 6 months. The study 
included direct costs related to PHN. Indirect costs were not included as most 
patients with PHN are older and retired. Transition probabilities were based on 
the comparative and long-term clinical trials. Utilites were identified through a 
literature review. Resource utilization was obtained from a two-step Delphi study 
with pain specialists, cost data were obtained from the official price tariffs/lists. 
Extensive sensitivity and scenario analyses were performed to explore robustness of 
the results. Results: In 6-month time horizon, treatment with the lidocaine plaster 
yielded 0.4283 QALYs. For pregabalin and amitriptyline the total effect was 0.3390 
QALYs. The mean costs per patient treated with lidocaine plaster (1.71 plasters/day) 
were 1,082 € . For pregabalin (488 mg/day) and amitriptyline (25 mg/day) the mean 
costs were 912 € and 346 € , respectively. Therefore, the lidocaine plaster compared 
to pregabalin and amitriptyline had an incremental cost-effectiveness ratio of 1,907 
€ /QALY and 8,246 € /QALY, respectively. Probability of the lidocaine plaster being 
cost-effective versus pregabalin and amitriptyline exceeded 90% when considering 
a threshold of 30,000 € per QALY gained. Extensive scenario and one-way sensitivity 
analyses confirmed robustness of the results. cOnclusiOns: The lidocaine 5% 
plaster is a highly cost-effective treatment for PHN in the Netherlands.
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Objectives: The main objective was to perform a pharmacoeconomic analysis 
to find out the cost effectiveness of diethylpropion (DEP) with diet and exercise. 
(DEP+DaE), compared against Diet and Exercise (DaE) in the treatment for obesity 
from the institutional point of view in Mexico. MethOds: Effectiveness data from 
a mexican clinical trial (Morin, 2007) was used to populate a decision tree model 
to estimate the cost-effectiveness of DEP+DaE and its comparator DaE. The target 
population were men and women over 18 years with BMI > 30 kg/m2. Principal 
outcome was the reduction of the Body Mass Index (BMI); benefit was expressed as 
the percentage of patients who reduced more than 10% of their initial weight. Only 
direct medical costs were used, such as medications and adverse events; these were 
obtained from the portal shop by IMSS and also from their unitary costs. To prove the 
Years Gained - LYG) and cost-utility analysis (Quality- Adjusted Life years – QALYs) 
were performed for a time horizon of 10 years according to a Markov economic 
model with four health states - “progression free survival (PFS) in first and second 
lines”, “progression” and “death” - and monthly cycles. Health states transition 
probabilities were obtained from two randomized controlled clinical trials: PRIMA 
(Salles G. et al 2010) and EORTC 20981 (van Oers M. et al 2010). Health state utili-
ties were obtained from literature (Pettengell R. et al 2008). Resource consumption 
was estimated by a Portuguese expert’s panel. Costs were calculated considering 
the Portuguese Health System perspective through official data (unit costs: € in 
2014). Costs and consequences were discounted at 5% per annum. Deterministic 
and probabilistic (Monte Carlo simulation) sensitivity analyses were performed for 
several assumptions namely time horizon, PFS supportive care and progression 
costs; adverse events costs; health states utilities values and costs and benefits 
annual discount. Results: For a 10 years’ time horizon, the cost per LYG and QALYs 
gained was € 10,630 and € 10,674 respectively. Sensitivity analyses confirmed the 
base case results for time horizons of 20 and 30 years, ranging between € 7,430 and 
€ 7,155 per QALY gained, respectively. Probabilistic sensitivity analysis confirmed 
the robustness of the model with a cost per QALY gained of € 10,657. The incre-
mental cost-effectiveness acceptability curve shows that rituximab maintenance 
therapy would be cost effective from a willingness to pay of € 12,000 per QALY 
gained. cOnclusiOns: According to the present model rituximab maintenance 
treatment of FL patients who respond to first line induction therapy compared with 
observation is a cost-effective strategy in Portugal.
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Objectives: The NHS newborn bloodspot screening programme currently screens 
all babies in England for five rare conditions. The objective of this study was to 
assess the cost-effectiveness of expanding the screening programme to include five 
new rare conditions all inborn errors of the metabolism; HCU, MSUD, GA1, IVA, and 
LCHADD. MethOds: A decision tree model was built to estimate the cost-effective-
ness of the expanded newborn screening programme. Estimates of the prevalence 
of the five conditions and the test characteristics of screening were taken from 
the literature. Survival and morbidity estimates for the screened and unscreened 
populations were estimated from published case series. Quality adjusted life years 
(QALYS) were estimated from the extended EQ-5D+ (C) which includes a cognitive 
dimension in order to capture the impact of neurological impairment and devel-
opmental delay which are known sequelae of the five conditions. Costs related to 
the marginal cost of the expanded screening programme, management costs of the 
conditions, and costs associated with the sequelae of the conditions were estimated 
from the pilot study of the expanded screening, case reports from the pilot, expert 
elicitation, published guidelines and estimates from the literature. Costs and QALYs 
were multiplied by survival and morbidity estimates to give lifetime estimates for 
the screened and unscreened populations. A probabilistic sensitivity analysis (PSA) 
was conducted. Results: The results from the deterministic analysis and PSA sug-
gests that screening for all five conditions is cost-saving with screening associated 
with lower total costs and higher total QALYs compared to no screening. The incre-
mental net benefit for all five conditions, at a threshold of £25,000 per QALY, was 
between £0.46 for IVA and £5.94 for GA1. cOnclusiOns: Screening for MSUD, HCU, 
IVA, GA1 and LCHADD are each estimated to be potentially cost saving and result 
in increased quality of life compared to no screening.
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Objectives: PNP is a high-burden disease exacerbated by poor tolerability of con-
ventional oral therapies. Capsaicin 8% patch is a well-tolerated cutaneous treat-
ment for PNP in non-diabetic adults either alone or in combination with other 
therapies. We evaluated the cost-effectiveness of capsaicin 8% patch versus pre-
gabalin in patients with PNP from the perspective of NHS Scotland. MethOds: A 
decision tree model was developed considering patients with PNP who had neither 
achieved pain relief nor tolerated conventional first-/second-line treatments. After 
8 weeks’ treatment with capsaicin 8% patch or pregabalin, patients remained on 
therapy or discontinued due to intolerable adverse events. Patients continuing on 
therapy were classified as either responders (≥ 30% decrease in pain from baseline) 
or non-responders. Last-line therapy was given to non-responders and those who 
discontinued treatment. The base-case time horizon was 2 years. Effectiveness, 
discontinuations and quality of life utilities were estimated from a recent head-to-
head study (ELEVATE; NCT01713426). Other inputs were obtained from published 
sources or clinical expert opinion. All costs were based on GBP 2013/14. The results 
were presented as incremental cost-effectiveness ratios (ICERs), i. e. cost per quality-
adjusted life-year (QALY) gained. Model assumptions were tested with scenario 
analyses. Parameter uncertainty was tested using one-way and probabilistic sen-
sitivity analyses. Results: Compared with pregabalin, capsaicin 8% patch was 
dominant versus pregabalin (total cost difference, –£11 and total QALY gains, +0.049). 
Using a 1-year time horizon, the ICER increased to £1,242/QALY. The model was most 
sensitive to variations in time to capsaicin 8% patch retreatment (worse case ICER, 
£7,951/QALY). Capsaicin 8% patch was dominant in six/seven scenario analyses. 
At a willingness-to-pay threshold of £20,000/QALY gained, the probability of cost-
effectiveness for capsaicin 8% patch versus pregabalin was 97%. cOnclusiOns: 
